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ADPKD is erroneously perceived as a not rare condition, which is mainly due to the repeated
citation of a mistaken interpretation of old epidemiological data, as reported in the Dal-
gaard’s work (1957). Even if ADPKD is not a common condition, the correct prevalence of
ADPKD in the general population is uncertain, with a wide range of estimations reported by
different authors. In this work, we have performed a meta-analysis of available epidemiologi-
cal data in the European literature. Furthermore we collected the diagnosis and clinical data
of ADPKD in a province in the north of Italy (Modena). We describe the point and predicted
prevalence of ADPKD, as well as the main clinical characteristics of ADPKD in this region.
Methods
We looked at the epidemiological data according to specific parameters and criteria in the
Pubmed, CINAHL, Scopus and Web of Science databases. Data were summarized using
linear regression analysis. We collected patients’ diagnoses in the Province of Modena
according to accepted clinical criteria and/or molecular analysis. Predicted prevalence has
been calculated through a logistic regression prediction applied to the at-risk population.
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Results
The average prevalence of ADPKD, as obtained from 8 epidemiological studies of sufficient
quality, is 2.7: 10,000 (CI95 = 0.73–4.67). The point prevalence of ADPKD in the province of
Modena is 3.63: 10,000 (CI95 = 3.010–3.758). On the basis of the collected pedigrees and
identification of the at-risk subjects, the predicted prevalence in the Province of Modena is
4.76: 10,000 (CI 95% = 4.109–4.918).
Conclusion
As identified in our study, point prevalence is comparable with the majority of the studies of
literature, while predicted prevalence (4.76: 10,000) generally appears higher than in the
previous estimates of the literature, with a few exceptions. Thus, this could suggest that
undiagnosed ADPKD subjects, as predicted by our approach, could be relevant and will
most likely require more clinical attention. Nevertheless, our estimation, in addition to the
averaged ones derived from literature, not exceeding the limit of 5:10,000 inhabitants, are
compatible with the definition of rare disease adopted by the European Medicines Agency
and Food and Drug Administration.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is recognized as the most frequent
Mendelian kidney disease. In Europe, ADPKD is the fourth diagnosis for both the incidence
and prevalence of renal diseases that require replacement therapy [1] and 1 in 10 patients
needing renal replacement therapy has ADPKD [2]. The predominant phenotype of ADPKD
is the accumulation of cysts in renal parenchyma, however, a number of other events accom-
pany the condition such as cysts in other organs, (liver, pancreas, spleen, seminal vesicles, and
arachnoid membrane), cardiovascular abnormalities (intracranial aneurysms, aortic root dila-
tation and aneurysms, mitral valve prolapse), abdominal wall hernias and other rarer pheno-
types (epididymal cysts, etc.). The condition is genetically heterogeneous and is caused by the
mutation of two polycystin genes, PKD1 and PKD2 [3, 4] and much more rarely by two other
recently identified genes: GANAB [5], PMM2 [6]. The genetic defect of ADPKD subverts the
normal differentiated phenotype of renal tubular epithelium. Cyst accumulation and growth
replaces normal kidney parenchyma in a complex process that is accompanied by fibrosis and
interstitial inflammation.
The research question posed by this study concerns the prevalence of ADPKD in European
territory. A correct understanding of the epidemiology of a condition is central to many
aspects of the health organization and clinical research concerning the same condition (e.g., a
program of clinical trials, access to orphan drugs designation, the implementation of specific
emerging treatments, the evaluation of the performance of treatment, etc.). In the past, in the
introduction of their works, many authors have frequently reported a prevalence of ADPKD
between 1/400 and 1/1000, thus referring to Dalgaard’s seminal work[7]. In fact, Dalgaard did
not ascertain the point prevalence of ADPKD but rather estimated a morbid risk—the theoret-
ical risk of being ill from ADPKD during a lifetime of 80 years duration. Dalgaard’s paper has
long been misunderstood, and based on this equivocation, ADPKD was incorrectly considered
as a peculiarly frequent condition in spite of being a genetic disorder. In ADPKD, available
epidemiological estimates are conflicting and prevalence is uncertain. The evaluation of the
The prevalence of autosomal dominant polycystic kidney disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0190430 January 16, 2018 2 / 20
Funding: This study was partially funded by a grant
provided by the Italian Ministry of Health (Ricerca
Finalizzata Protocol RF-2013-02356802). The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript. The remaining funding of this work
was covered by the Institute’s internal resources of
the last author. There was no additional external
funding received for this study.
Competing interests: The authors have declared
that no competing interests exist.
prevalence of ADPKD is challenging, and this difficulty is fully reflected in the broad range of
estimations reported by different authors over the years[7–22]. There are different approaches
to estimating disease occurrence in a population. The choice of approach will depend on many
different factors, such as the amount of patient data available and the accuracy of the result
required.
In this paper, we have performed a meta-analysis of the epidemiological data (cohort stud-
ies of prevalence of ADPKD in the general population) in the available literature. Furthermore
we evaluated the prevalence of ADPKD in a circumscribed geographic region of northern
Italy. In particular, we focused on identifying all the affected and at-risk subjects, starting from
the pedigrees of the index cases. Furthermore, we present an unprecedented strategy for the
management of missing diagnosis in the ADPKD epidemiology. Our analysis allows us to
safely confirm that ADPKD can be considered a rare disease, in terms of the criteria required
by the European Medicine Agencies (EMA) and Food and Drug Administration (FDA).
Materials and methods
Selection criteria of the available literature
Articles in English language (at least in the abstract section, in case of interesting articles with
full article in other language than English a translation has been obtained) reporting epidemio-
logic data of patients affected by ADPKD in the general population of the European Union
countries were considered eligible.
We performed searches of four electronic databases in order to identify high-quality epide-
miologic studies published on ADPKD: the National Library of Medicine PubMed database,
the Web of Science database, the Scopus database and the CINAHL database.
The search used the Medical Subject Heading terms ‘Polycystic Kidney’, Autosomal Domi-
nant’ or ‘Polycystic Kidney Diseases and ‘incidence study’ or ‘prevalence study’ or ‘epidemio-
logic study’ and encompassed all studies published between January 1980 and February 2017,
as ultrasound and other modern diagnostic methods for ADPKD detection were available dur-
ing this timeframe. The research strategy has been adapted according to the specific query
structure of each database. In detail the adopted search strategies are:
NLM PubMed: ((ADPKD OR ("Polycystic Kidney Diseases"[Mesh]) OR "Polycystic Kid-
ney, Autosomal Dominant"[Mesh])) AND ("Epidemiologic Studies"[Mesh]OR "Cross-Sec-
tional Studies"[Mesh] OR "Cohort Studies"[Mesh] OR (prevalence[Title] OR epidemiology
[Title]))
Filters: Publication date from 1980/01/01 to 2017/02/28)).
Cinahl: (ADPKD OR MH "polycystic kidney disease+" OR MH "Polycystic Kidney, Autoso-
mal Dominant+") AND (MH "Epidemiologic Study+" OR MH "Cross-Sectional Study+" OR
MH "Cohort Study+" OR TI "prevalence" OR TI "epidemiology")
Filters: Publication date from 1980/01/01 to 2017/02/28)).
Scopus: ((ABS(ADPKD) OR ABS(autosomal dominant polycystic kidney disease)) AND
((ABS(epidemiology) OR ABS(Epidemiologic Study) OR ABS(Cross-Sectional Study) OR ABS
(Cohort Study))))
Filters: Publication date from 1980/01/01 to 2017/02/28)).
Web of Science: ((TI = (ADPKD) OR TI = (autosomal dominant polycystic kidney disease)
OR (TS = (ADPKD) OR TS = (autosomal dominant polycystic kidney disease)) AND ((TI =
(epidemiology) OR TI = (Epidemiologic Study) OR TI = (Cross-Sectional Study) OR TI =
(Cohort Study) OR (TS = (epidemiology) OR TS = (Epidemiologic Study) OR TS = (Cross-
SecTSonal Study) OR TS = (Cohort Study))))
Filters: Publication date from 1980/01/01 to 2017/02/28)).
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Further reports were added to the list of available literature following a manual review of
the citations from relevant studies.
Criteria used to select relevant studies from the preliminary list included: selection of popu-
lation-based studies and registry data, epidemiologic reviews, validity studies, studies of clini-
cal characteristics in large patient samples. In addition, an adequate sampling and power
analysis, an appropriate denominator for prevalence estimates and a contemporary and largely
accepted ADPKD definition were required (according to Pei, Obaji et al. 2009 19, Pei, Hwang
et al. 2015 20).
The papers have been reviewed by two independent researchers according to the previous
criteria. Data have been extracted in piloted forms. Quality of the studies was assessed by a
standardized scale (Newcastle-Ottawa scale). A detailed report of the assessment is reported in
the Table I in S1 File of the supplemental material. In the Table A–H in S1 File of the supple-
mental material a synthetic report of the Newcastle-Ottawa scale is reported for each study.
Disagreements between the review authors in particular studies were resolved by discussion,
with involvement of a third review author where necessary.
The following data items have been collected from the selected articles: Type of Source,
Region, Collection Year(s), Case definition, Data Collection Method, Design, Reference Popu-
lation, Risk Factors, Incidence, Renal Replacement Therapy, Mortality, Point Prevalence Pre-
dicted Prevalence (PrP). These data are tabulated in Table A–H in S1 File of the supplemental
materials.
Identification of affected patients in the province of Modena
The study has been approved by the Ethical Committee of the Province of Modena under the
name ‘GREAt’ (GRoup for Epidemiological study in ADPKD). Before clinical evaluation and
data collection, patients received adequate information and signed an informed consent form.
Data were collected extensively from different sources: Administrative Electronic Databases of
Outpatient Clinics and Hospital Admission, Renal Replacement Therapy Registry (http://
www.regdial.it/) and Radiologic Databases. Subjects diagnosed with the Renal Cyst condition
were singularly reviewed. For Outpatient Clinics of small centers without data capture based
on Electronic Databases, the hard copies of medical notes have been reviewed to identify
patients with a diagnosis related to ADPKD.
Inclusion criteria for patients were based on imaging evaluation by ultrasound according to
Pei et al. [23] and MRI diagnostic criteria, as reported by Pei et al.[24]. Details of the criteria
are reported in the Supplemental Materials (Appendix A in S1 File of the supplemental
material).
In the uncertain cases where a genetic test with a conclusive identification of a likely patho-
genic or pathogenic variant [25] was available, it has been accepted to confirm the diagnosis.
Strategy for patient identification
1) Searching all the available clinical sources initially allowed the identification of index cases;
2) we then collected pedigree information from the index cases and identified all of the at-risk
subjects; 3) finally, we collected the clinical information of index cases and at risk subjects by
summoning them for a clinical visit and/or collecting data from available clinical databases
(specifically, the radiologic archives).
Statistical analysis
Meta-analysis. Linear regression has been adopted to combine prevalence between the
selected epidemiologic studies (Stata/IC 11.2, Stata Corp, Tx, USA). Combined prevalence
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between studies has been obtained as coefficient of the linear regression of patients against
population with 95% confidence intervals. Quantitative assessment of study heterogeneity has
been assessed using Cochran’s Q. Q is the weighted sum of squares on a standardized scale.
This test has low power to detect heterogeneity and it is suggested to use a value of 0.10 as a
cut-off for significance[26]
Epidemiologic study. Binary Logistic Regression (Marginal Standardization Method)
[27] was used to predict the probability of the occurrence of the event “presence of ADPKD”
in the at-risk population. The objective of the analysis was to determine, using logistic regres-
sion the relative contribution of independent variables (predictors) according to the intensity
of their influence (proven by statistical significance) upon the occurrence of values of the
dependent ADPKD risk scores.
The quality of the model was judged by examining the overall significance of the model.
This could be done by testing the hypothesis (H0:β = 0) which means that all the regressor
were insignificant on ADPKD. We have rejected this hypothesis, indicating that the regressors
have got significant effect on ADPKD.
By the procedure of curve estimation we have produced regression statistics and a related
separate model was produced for each dependent variable. The model also saved the predicted
values and the 95% prediction intervals. We have estimated the predicted prevalence rates and
the 95% prediction intervals.
We refer readers who wish to apply marginal standardization using SAS (SAS Institute Inc.,
Cary, NC) to a macro described elsewhere [27]. The PROCRLOGIST command in SAS-call-
able SUDAAN (Research Triangle Institute, Research Triangle Park, NC) can implement Mar-
ginal Standardization.
Missing data (age). As recommended by EMA’s guideline on missing data in the case of
continuous variables (EMA/CPMP/EWP/1776/99), linear mixed models (LMMs) have been
used to impute missing values. The peculiarity of LMMs lies in the way parameters are treated.
This model assume that model’s parameter (age) is composed of a fixed term (a mean value
common to all individuals) plus a random effect (which conveys the between-subject variabil-
ity). Affected (with age AND gender, after LMMs procedure) N = (238 + 16) = 254. All the sub-
jects “Affected Clinically Defined” (N = 254) contribute to the Prevalence Rate. The model is
assessed by comparing the calculated prevalence with the observed data by gender. Clinically
Defined Population (N = 254).
Age and sex-specific prevalence. Age and sex-specific prevalence rates of ADPKD were
computed as the ratio of the number of cumulative cases identified divided by the population
for age and sex-specific groups. To estimate the prevalence of ADPKD we fitted a non-linear
regression model, including age (in 5-year groups) and gender. We summarized prevalence
rates separately for men and women by estimating an individual’s probability of being diag-
nosed with ADPKD during her or his lifetime (lifetime risk). This measure is an overestima-
tion of the true lifetime risk, since dying from other causes reduces the cumulative probability
of developing ADPKD in a population. This methodology allows the estimation of age-condi-
tional probabilities of developing ADPKD taking into account that individuals dying from
causes other than the disease of interest cannot develop that disease in the future (as a conse-
quence, the adjusted lifetime risk is lower than the non-adjusted value).
The distribution of the cumulative risk to be affected according to age and differentiated by
sex is represented in Fig A in S1 File of the supplemental material.
Family Risk Score. The Family Risk Score was defined as the ratio of affected subjects com-
pared to those at risk in a family. This parameter has been calculated in all the collected pedi-
grees. The predicting value of this parameter relies on the well documented role of genetic
variant in the severity of the condition. This is reported for the locus effect (PKD1 / PKD2
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contribution) [28] as well as for the allele effect (role of the type of variant (missense / truncat-
ing) especially in PKD1 subjects [29, 30]. By the assumption that a family share the same type
of mutation we inferred that there is a familiar risk contribution that we approximated in the
Family Risk Score. Fig B in S1 File of the supplemental material represents the distribution of
the Family Risk Score in our families. The Family Risk Score has not been calculated in the
sporadic cases (absence of family history). In the logistic regression model the Family Risk
Score has been adjusted for the percentage of subjects without a family history (15%).
Genetic analysis. Genetic analysis for PKD1 and PKD2 were available for a subset of sub-
jects. The test was based on the sequencing of the two genes—whole coding regions and exon
junctions—using the Sanger direct method. Methods have been extensively reported in a pre-
vious paper of our group [31]. All genetic and phenotypic data have been anonymized and
uploaded to an electronic database (LOVD3.0 platform)[32, 33] that is publicly available
(https://databases.lovd.nl/shared/genes/PKD1; https://databases.lovd.nl/shared/genes/PKD2).
Details on the molecular genetic methods are provided in the Supplemental Materials section.
Results
Available epidemiologic data and combined analysis
We performed an extensive literature research based on a database search and by manually
checking the references of the identified articles. In all, 926 citations were identified, of which
916 were excluded according to the selection criteria. In particular, some studies encompassed
renal cystic conditions other than ADPKD (e.g., ARPKD or Tuberous Sclerosis Complex), or
were otherwise clinical studies based on small or methodologically flawed samples. Of the ana-
lyzed ten full-text articles one was excluded because of an unacceptable clinical definition of
ADPKD [Heidland, Bahner et al. 2009[11]], the second because of the absence of a reference
population [World 2012] [20]). According to these criteria, eight population-based studies
have been selected for data analysis. The Prisma [34] flowchart for the selection of the available
studies is depicted in Fig 1. The main data of these studies are tabulated (Table A–H in S1 File)
in the Supplemental Materials section.
Table 1 summarizes the point prevalence and predicted prevalence that is either directly
reported or indirectly obtainable from the data of these selected publications. ‘Predicted Preva-
lence’ represents the effort of the authors to handle missing diagnoses using heterogeneous
methodological approaches. These data are available in two analyzed articles [9, 10]. Where
not available, the point prevalence has been used in the following analysis. The same data are
represented in Fig 2. We performed a linear regression of the ADPKD population over the ref-
erence population reported in the articles. Fig 3 plots the estimations of the reported preva-
lences. After linear regression, the combined prevalence of these studies is 2.7: 10,000 subjects
(CI 95: 0.73–4.67: 10,000 subjects). The Cochran’s Q suggests heterogeneity between studies
(Q = 184.78; p<0.001).
Point prevalence of ADPKD in the province of Modena
According to the data sources described in the methods section, we identified 238 index cases
belonging to 184 different families. We made an attempt to contact each of these subjects and
invited them for a visit in our center. All the patients that accepted to be enrolled in the study
and to be interviewed signed the consent form. The clinical evaluation of the compliant sub-
jects (141 individuals, 59.3%) allowed us to collect 99 pedigrees; however, in the remaining
cases it was neither possible to contact the subject nor extract an address or phone number of
66 subjects from the source (27.7%); also, 21 subjects did not reply to phone or mail invitation
to the study (8.8%). Ten subjects have not been compliant to a clinical visit in our center
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(4.2%). This initial data collection and pedigree analysis generated a list of 493 subjects
reported as either affected (238 subjects) or at-risk subject of ADPKD (255 subjects) (see
Table 2).
After completion of the clinical visits, 16 at-risk subjects resulted in being actually affected
according to imaging (US or MRI diagnosis). In 43 at-risk subjects, the diagnosis was excluded
by imaging and six subjects were excluded on the basis of a genetic test. Twenty-one at-risk
subjects did not reveal any conclusive imaging or genetic tests. After the clinical evaluation of
Fig 1. Flow of information through the different phases of the selection of available studies.
https://doi.org/10.1371/journal.pone.0190430.g001
Table 1. Selected epidemiological studies.
Reference [9] [10] [15] [16] [18] [14] [35] [22]








4.06: 10,000 3.31: 10,000 NA NA NA NA NA NA













Point prevalence, predicted prevalence and geographic region of the selected epidemiological studies[9, 10, 14–16, 18, 22, 35]
https://doi.org/10.1371/journal.pone.0190430.t001
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the compliant subjects, affected patients totaled 254. According to the National Institute of Sta-
tistical (ISTAT, 2016), the population of the Province of Modena, comprises 701,642 inhabi-
tants. According to a more conservative calculation considering only the clinically defined
affected patients, the point prevalence can be reported as 3.63: 10,000 (CI 95% = 3.010–3.758).
This estimate shows the prevalence of clinically diagnosed and probably underestimates the
real prevalence because of a number of underdiagnosed subjects. Considering that patients
with stage 1 and 2 of renal failure were more likely to be underdetected, we performed a sensi-
tivity analysis, assuming percentages of subjects in stage 1–2 of 40%, 50% and 60%. In these
three scenarios, the prevalence varies from a minimum of 3.97 to a maximum of 5.96: 10,000
inhabitants (see Table J in S1 File in supplemental material for details)
Predicted prevalence of ADPKD in the province of Modena
The strategy adopted for the estimation of the Predicted Prevalence of our population is sum-
marized in Fig 4. The process preliminarily required the imputation of missing data (age,
Fig 2. The figure depicts the predicted prevalence reported in the selected epidemiological studies[9, 10, 14–16, 18, 22, 35]. Point prevalence was
reported if predicted prevalence was not available. the dotted line indicates the limit of 5 cases: 10,000 inhabitants adopted by EMA to define rare disease.
https://doi.org/10.1371/journal.pone.0190430.g002
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gender, Family Risk Score; see Materials and Methods for a definition and calculation of the
Family Risk Score) using a linear mixed model both in the clinically-defined affected subjects
Fig 3. Plot of the ADPKD subjects over the reference population reported in the selected articles ([9, 10, 14–16, 18, 22, 35]). Dashed line represents
linear regression of the plotted points.
https://doi.org/10.1371/journal.pone.0190430.g003







255 With Exams: 86 Affected (Post Test) 16■ 16
Undefined (Post Test) 21■
Not Affected (Post Test) 43■+6▲
Without Exams: 169 (Undefined Pre Test)
TOTAL 254
Summary of 493 subjects collected during the survey. In 85 patients in the at-risk group, diagnostic tests (imaging exam■ and/or genetic test▲) were
available.
https://doi.org/10.1371/journal.pone.0190430.t002
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and in the at-risk population. Finally, a logistic regression model based on a set of predictor
variables (age, gender, Family Risk Score) was used to predict the outcome (affected status) in
the at-risk population.
Finally, the age-adjusted prevalence rate was defined by considering the age distribution of
the population of the Province of Modena, according to ISTAT survey performed in January
2016.
Applying the Logistic Regression model, we calculated the expected number of affected
patients in the at-risk population that had not participated in an instrumental exam (pretest
population). Based our findings, we noted that 79 of 190 (41.6%) subjects would be affected in
the at-risk population. The overall number of predicted affected patients (254+79 subjects)
Fig 4. Flow chart of the statistical approach for the calculation of the predicted prevalence of ADPKD.
https://doi.org/10.1371/journal.pone.0190430.g004
The prevalence of autosomal dominant polycystic kidney disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0190430 January 16, 2018 10 / 20
resulted in 333 estimated ADPKD subjects. Accordingly, the Predicted Prevalence can be esti-
mated in 4.76: 10,000 inhabitants (CI 95% = 4.109–4.918).
The Family Risk Score incorporates the rate of subjects without a family history that in our
population is 15.1% and it is approximated to 15% in the model. Furthermore we have
adjusted this value from 10% to 15% and to 20% in a sensitive analysis to verify the impact of
this factor in our prediction (see Table 3).
Characteristics of the cohort
The compliant patients that accepted a complete clinical evaluation numbered 141 (55.5%)
subjects out of 254 identified ADPKD subjects. Table 4 reports the main characteristics of this
Table 3. Sensitivity analysis of predicted prevalence according to variation of the percentage of ADPKD subjects without family history.
PERCENTAGE OF SUBJECTS WITHOUT FAMILY
HISTORY
PREDICTED PREVALENCE IN 10,000
INHABITANTS






Table 4. The major clinical characteristics of the cohort.
M:F 1.085: 1







5 53 (37.5%) 43 of 53 requiring RRT:
- Hemodialysis: 18
(41.9%)




Presence of Hypertension 119 (84.7%)
Age of Hypertensive state onset (years) 39 (30–49)











Data are expressed as Median (25˚-75˚) or number of subjects(%).
* Data of 50 patients were available for Total Kidney Volume.
▲ The data of 36 subjects were available for the PKDSCORE.
https://doi.org/10.1371/journal.pone.0190430.t004
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population. A positive family history of ADPKD is present in 120 subjects (84.9%). We found
that the male gender is slightly more frequent, with a median age of the cohort being 56.1
years. Forty-three patients (30.5%) were in renal replacement therapy, with transplantion
being the most prevalent approach: 20 patients (46.5%). The median age of starting renal
replacement therapy is 54 years (25˚-75˚ 47–62 years). Gender is neither significantly different
in the male/female ratio of subjects in RRT (16 females, 27 males; p 0.196), nor in the age of
starting RRT (female median 55 years [25˚-75˚ 49–61.5 years]; male median 52 years [25˚-75˚
42–62 years]; p 0.529), although both parameters are tendentially worse in subjects of male
gender.
Hypertension is a common complication that is reported in 119 patients (84.7%). The
median age of onset of this condition is 39 years. Hypertension is slightly less common in
females (80.6%) than males (88%); however, age of onset is not statistically different between
genders (p 0.693). Kidney Volume was available for 50 patients included in this study. Accord-
ing to the Mayo Clinic ADPKD score [36], patients in class 1B, 1C, and 1D each represent
approximately 30% of the sample, while patients in class 1A and 1E are less common (see
Table 4).
Twelve cases indicated a positive family history of cerebral aneurysm, while two more sub-
jects reported a positive family history for subarachnoid hemorrhage. Five subjects reported
the presence of aneurysms (none of them had a positive family history for intracranial aneu-
rysms). One subject reported a previous subarachnoid hemorrhage (without a positive family
history). Forty-one subjects reported a negative MRI cerebral scan, while the remaining cases
never underwent a neuroradiologic examination having a negative family history.
Genetic analysis
Genetic analysis for PKD1 and PKD2 were available on a subset (42 subjects) of at-risk or
affected subjects in our cohort (Table 5). In 23 patients, we performed the complete analysis of
both genes using Sanger sequencing, while in 19 related patients, we evaluated the segregation
analysis of the previously-identified pathogenic variant of the family. Six of these 19 patients
resulted negative at molecular analysis and were classified as not affected.
Characteristics of the variants for each of the genotyped subjects are reported in Table 5.
The distribution of the PROPKD score [30] is reported in Table 4. Renal survival is modified
by mutation classes (p<0.001) (the number of truncating and not truncating variants are
reported in Table K in S1 File of the supplemental material, while the survival curves are repre-
sented in Fig 5.
Discussion
This work is, to our knowledge, the first attempt to produce a meta-analytical synthesis of the
epidemiological literature available in Europe on ADPKD prevalence in the general popula-
tion. Furthermore the estimation of missing data (predicted prevalence) has been obtained in
our cohort by an unprecedented strategy (logistic regression prediction). ADPKD epidemiol-
ogy is a controversial topic with highly variable estimates of prevalence in the available litera-
ture, ranging from 1.44: 10,000 [9] to 25: 10,000 [4]. Several reasons may concur this
variability. The major factor that introduces uncertainty in estimates is the presence of a signif-
icant proportion of affected but asymptomatic patients (patients that will become clinically evi-
dent later in their life) and the lack of a simple and inexpensive population screening tool.
Other components of the analysis may introduce variability in the epidemiology of ADPKD;
for example, the nature of the sources used in patient research, and the epidemiological and
statistical techniques used to remedy missing data, etc. Finally, the regional variability of the
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Table 5. Table of genetic variants identified in the cohort.
Patient
ID
Sequencing Variant (c.DNA) Exon/
intron






1 complete c.393_394del TG 4 p.Cys131Trpfs*47 T frameshift Definitely
Pathogenic
Pathogenic





3 complete c.2884delG 12 p.Asp962Thrfs*14 T frameshift PKD domain Pathogenic










6 complete c.4551C>A 15 p.Tyr1517* T nonsense PKD domain Definitely
Pathogenic
Pathogenic
7 complete c.5477G>A 15 p.Trp1826* T nonsense PKD domain Definitely
Pathogenic
Pathogenic
8 complete c.8095C>T 22 p.Gln2699* T nonsense REJ domain Pathogenic



















13 complete c.12444+57_81del 45i T intronic Likely
pathogenic
14 complete c.194T>A 1 p.Ile65Asn NT missense Likely benign
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incidence of the disease can not be excluded, indeed at least the founder effect has been docu-
mented in small and isolated communities [21].
Hospital databases and the collection of data from clinical notes, which are frequently
adopted as epidemiological source material, necessarily introduce the bias of missing asymp-
tomatic ADPKD subjects. A population-wide imaging-based screening for ADPKD has never
been performed and it will probably never be done in consideration of the high costs. The
prevalence estimates reported target clinical cases mostly likely presented to nephrologists/
internists. Many patients with good kidney function cared by primary care physicians might
not be captured in the published literature and the same underestimation is highly probable in
the selected studies of our meta-analysis. However, in the epidemiological study of the prov-
ince of Modena, we have attempted to reduce this bias both in the point and in the predicted
estimation by two different strategies: the detailed reconstruction of the pedigrees of our index
cases and the prediction of affected cases by a logistic regression model. Logistic regression is a
statistical tool useful to predict the presence or absence of an outcome (ADPKD) based on val-
ues of a set of predictor variables (age, gender, Family Risk Score). It is similar to a linear
regression model but is suited to models where the dependent variable is dichotomous (pres-
ence/absence of ADPKD). Gender and age are well recognized modifying variables of ADPKD




Sequencing Variant (c.DNA) Exon/
intron





25 complete c.11537+2T>A 41i T splicing Pathogenic
26 segregation c.6548c>t 15 p.Thr2183Ile NT missense Likely
pathogenic
27 segregation c.6548c>t 15 p.Thr2183Ile NT missense Likely
pathogenic
28 complete c.12061C>T 44 p.Arg4021* T nonsense Definitely
Pathogenic
Pathogenic
29 complete c.6307C>T 15 p.Gln2103* T nonsense Definitely
Pathogenic
Pathogenic









32 segregation c.2614C>T 14 p.Arg872* T nonsense Pathogenic
33 segregation c.2614C>T 14 p.Arg872* T nonsense Pathogenic
34 complete c.843+1G>T 3i T splicing Definitely
Pathogenic
Pathogenic
35 segregation c.843+1G>T 3i T splicing Definitely
Pathogenic
Pathogenic
36 complete c.1094+1G>A 4i T splicing Definitely
Pathogenic
Pathogenic
The PKDB database (Mayo Clinic) column reports the variant pathogenicity available at ‘http://pkdb.mayo.edu/’. ACMG column reports the pathogenicity
classification performed by our group according to Richards et al.[25]. Moecular analysis was performed in 42 subjects, 6 subjects with a negative
segregational result are not reported.
https://doi.org/10.1371/journal.pone.0190430.t005
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affected subjects, whereas ADPKD is most likely to be diagnosed in adult subjects compared to
pediatric subjects.
The Family Risk Score was defined as the ratio of affected subjects compared to those at
risk in a family. The predicting value of this parameter relies on the well documented role of
genetic variant in the severity of the condition. The same genetic variant, and its disease risk, is
shared by all the affected components of the same family. The value of the covariate “Family
Risk Score” is included in the logistic model and adjusted for possible cases without an appar-
ent family history (15% of cases).
The first part of our work consisted in a meta-analysis of epidemiological data of the litera-
ture. An extensive bibliographic research identified eight relevant articles. A synthetic analysis
of data extracted from this source allowed us to establish a prevalence of disease of 2.7: 10,000
subjects (CI 95: 0.73–4.67: 10,000 subjects). Although the meta-analytic approach permits to
evaluate a significant European reference population (over 13,000,000 subjects), the intrinsic
limit of this analysis is the heterogeneity of the epidemiological approaches used to estimate
the prevalence by the different authors.
Fig 5. Renal survival of patients according to the type of their variant.
https://doi.org/10.1371/journal.pone.0190430.g005
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To overcome the uncertainty of the estimate originating from a meta-analytic elaboration,
in the second part of our work we directly investigated the prevalence of the condition in our
region. One of the strengths of the epidemiological approach to this work has been the effort
of maximizing the collection of diagnosed subjects, mainly based on pedigree collection and
extensive database search; nevertheless, our approach may have suffered from bias. In particu-
lar, despite our attempt to contact each affected and at-risk subject, we still managed to clini-
cally evaluate a proportion of our cohort faraway from completeness, limited compliance
being an inherent weakness in this type of study. In consideration of the risk of missing diag-
nosis, our point prevalence (3.63: 10,000) most likely represents an underestimation of the real
prevalence of the condition. Our point prevalence is in line with the average estimates of the
majority of the previous epidemiological studies[9, 10, 14–16], with only two studies reporting
higher prevalence[18, 35]. In the attempt of correcting for the missing diagnosis, we calculated
an estimated prevalence by applying a prediction of affected subjects in the clinically uncharac-
terized at-risk population. Our estimated prevalence of ADPKD (4.76:10’000) represents the
highest estimation of all the previous epidemiological studies, with the only exception of the
French study [18]. A recent paper [37] compared population-based and renal registry studies
and concluded that, under specific assumptions (inflation rate, etc.), data are consistent
between the two approaches. They proposed an estimated prevalence of 3.96:10,000, a figure
close, but still lower than our predicted estimation. Interestingly, a public document produced
by the Committee for Orphan Medicinal Products (COMP—Minutes of the 16–18 June 2015
meeting) on the orphan drug designation of Lanreotide, a somatostatin analog for treatment
in ADPKD, reported a prevalence of between 4.2 and 4.7 in 10’000. Even if this document does
not provide details about the adopted epidemiological methods, it reports an interval that is
higher than the prevalent previous literature and particularly close to our confidence limits
(4.109 and 4.918 in 10’000). The significant divergence between point prevalence and pre-
dicted prevalence, as described in our study, suggests that there is a significant proportion of
unrecognized patients. In our analysis, these subjects could account for about 25% of the over-
all ADPKD population in our province. The fact that these patients did not come to clinical
attention does not mean that they would not deserve it. In fact, we can suspect that the pres-
ence of early and not symptomatic complications, such as hypertension or eligibility to specific
treatments [38] could be not uncommon in this category of undiagnosed subjects. However, it
is reasonable to predict that a proportion of these underdiagnosed subjects may have a milder
clinical picture compared to those already captured in clinical files.
The efforts made in this study to identify all affected patients in a defined geographical area
hopefully produced a more significant picture of the distribution of relevant clinical data com-
pared to some of the previous descriptions based on potentially biased collection (e.g., dialytic
populations, imaging archives, genetic registers, etc.). We have identified a relatively high fre-
quency of subjects without a family history of ADPKD (15.1%). This data is usually rarely
reported in the literature; for example, in the selected epidemiologic studies, [9, 10, 14–16, 18,
35] only 3 [9, 18, 35] report it in a range from 1.6% to 16%. One recent population-based study
has reported about 15% of cases with confirmed de novo mutation and another 10% without
an apparent family history [39]. In our study, the rate of family history of ADPKD was close to
the percentage of the HALT- PKD reports [40, 41]. Hypertension is the first complication for
age of onset and frequency in ADPKD. We found an elevated frequency (84.7%) of this com-
plication in our cohort, which was higher than previously reported (50–80%)[16, 42, 43], but
with a later median age of onset (9 years) than reported by Schrier et al.[44].
In our cohort, six subjects had intracranial aneurysms (one of them had a previous aneurys-
matic rupture) that represent a 4.2% of presence of this complication. Notably, none of these
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subjects reported a positive family history for intracranial aneurysms or subarachnoid
hemorrhage.
In conclusion, we conducted an epidemiological study that sought to maximize the identifi-
cation of the affected subjects using an in-depth pedigree analysis. We also adopted an unprec-
edented strategy to adjust our estimation of prevalence with respect to possible missing
diagnoses in at-risk subjects. The Point Prevalence (3.63:10,000) of our study is in line with the
average of the literature estimates. In contrast, predicted prevalence (4.76:10’000) indicates a
generally higher rate of disease than previously reported and suggests a significant proportion
of missed diagnoses in at-risk patients. This could be attributed to the low attention given by
nephrologists to family history and the reconstruction of the genealogical tree in outpatient
activity, which, on the contrary, has been extensively applied in our study. Nevertheless, our
prevalence estimates, which do not exceed the limit of 5:10,000 inhabitants, are still compatible
with the definition of rare disease adopted by the European Medicines Agency and Food and
Drug Administration.
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